Open access · CC-BY
via OpenAlex
Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection
Kamlesh Bhatt, Madhuri Bhagavathula, Sheetal Verma, Graham S. Timmins, Vojo P. Deretic, Jerrold J. Ellner, Padmini Salgame
Disease Models & Mechanisms · 2021 · ▲ 25 citations
Abstract
Tuberculosis (TB) treatment regimens are lengthy, causing non-adherence to treatment. Inadequate treatment can lead to relapse and the development of drug resistance TB. Furthermore, patients often exhibit residual lung damage even after cure, increasing the risk for relapse and development of other chronic respiratory illnesses. Host-directed therapeutics are emerging as an attractive means to augment the success of TB treatment. In this study, we used C3HeB/FeJ mice as an experimental model to investigate the potential role of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition), a mammalian target of rapamycin inhibitor, as an adjunctive therapy candidate during the treatment of Mycobacterium tuberculosis infection with moxifloxacin. We report that administration of rapamycin with or without moxifloxacin reduced infection-induced lung inflammation, and the number and size of caseating necrotic granulomas. Results from this study strengthen the potential use of rapamycin and its analogs as adjunct TB therapy, and importantly underscore the utility of the C3HeB/FeJ mouse model as a preclinical tool for evaluating host-directed therapy candidates for the treatment of TB.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1242/dmm.049018
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Bhatt, K., Bhagavathula, M., Verma, S., Timmins, G.S., Deretic, V.P., Ellner, J.J., & Salgame, P. (2021). Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection. <em>Disease Models & Mechanisms</em>. https://doi.org/10.1242/dmm.049018
Vancouver
Bhatt K, Bhagavathula M, Verma S, Timmins GS, Deretic VP, Ellner JJ, et al. Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection. Disease Models & Mechanisms. 2021. doi:10.1242/dmm.049018.
BibTeX
@article{kamlesh2021Rapamy,
title = {Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection},
author = {Kamlesh Bhatt and Madhuri Bhagavathula and Sheetal Verma and Graham S. Timmins and Vojo P. Deretic and Jerrold J. Ellner and Padmini Salgame},
journal = {Disease Models & Mechanisms},
year = {2021},
doi = {10.1242/dmm.049018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of British Columbia 2010
Open access · US-GOV
An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease
Human Molecular Genetics 2017
Open access · OA
Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID
Chemico-Biological Interactions 2020
Preprint · OA
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19
PLoS ONE 2020
Open access · CC-BY
Hydrogen extends Caenorhabditis elegans longevity by reducing reactive oxygen species
Memory Pharmaceuticals 2005
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease
Frontiers in Pharmacology 2018
Open access · CC-BY